Dimethyl fumarate, an FDA-approved medication for multiple sclerosis, recently demonstrated GSDMD inhibitory activity through covalent modification, presenting immediate repurposing potential for COPD management (20). The gene discussed is GSDMD; the disease is chronic obstructive pulmonary disease.